NCT02488408 2024-12-19A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSBerGenBio ASAPhase 1/2 Completed122 enrolled 29 charts
NCT03824080 2021-12-21Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesGWT-TUD GmbHPhase 2 Completed45 enrolled